Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes

Introduction Defibrotide (DF) is a polyribonucleotide with antithrombotic, pro-fibrinolytic, and anti-inflammatory effects on endothelium. These the established safety of DF present as strong candidate to treat viral post-infectious syndromes involving endothelial dysfunction.Areas Covered We discuss other therapeutic agents that have potential target components pathogenesis in syndromes. introduce defibrotide (DF), describe its mechanisms action, explore pleiotropic pathophysiology Coronavirus Disease 2019 (COVID-19) highlight processes specific COVID-19 potentially modulated by DF. also influenza A hemorrhagic fevers, especially those caused hantavirus, Ebola virus, dengue which might serve benefit. Finally, we offer our opinion novel treatment strategies targeting dysfunction infections their severe manifestations.Expert Opinion Given critical role numerous infectious syndromes, particular COVID-19, pharmacology for these conditions should increasingly prioritize stabilization. Several protective properties be further studied treatments vasculitides, where modalities failed.